Polymer Group to acquire Tesalca-Texnovo nonwovens businesses from Grupo Corinpa

NewsGuard 100/100 Score

Polymer Group, Inc. (OTC Bulletin Board: POLGA; POLGB) (PGI) today announced it has signed a definitive agreement to acquire the Barcelona, Spain-based Tesalca-Texnovo nonwovens businesses from Grupo Corinpa, S.L. in a two-phase process. The purchase is expected to close by the end of November, subject to customary closing conditions.

In conjunction with the transaction, PGI and Grupo Corinpa will initiate a long-term partnership that includes share ownership by Grupo Corinpa in PGI and representation on the PGI board of directors.

The businesses will be operated as a new wholly owned subsidiary (PGI Spain) and will have in excess of 50,000 metric tonnes of combined capacity. The acquisition furthers PGI's strategy of strengthening its position as the global leader in the hygiene market by increasing its presence in Europe, the world's largest volume market, and bringing it into new markets in Western Europe and Northern Africa where Tesalca-Texnovo has a strong customer base. After the consummation of the transaction, PGI's global spunlaid capacity will be in excess of 285,000 metric tonnes.

Texnovo was founded in 1989 as a family-owned private business focused on the industrial segments and the Tesalca business operations were added a decade later to supply the hygiene and medical segments. With approximately 280 total employees and combined 2008 annual sales of approximately $87 million, Tesalca-Texnovo is the only organization that manufactures spunbond polypropylene nonwoven materials in Spain and is a leader in the European market.

The Tesalca-Texnovo operations are headquartered in Barcelona and operate two plants in Tarragona, Spain on the same property, with six Reifenhauser Reicofil lines serving the hygiene, medical and industrial/agricultural segments.

"This acquisition will give us a larger platform for growth in this part of the world and will further our strategy to be the global hygiene leader," said Veronica (Ronee) Hagen, PGI's chief executive officer. "The Tesalca-Texnovo business is a good fit with our hygiene, medical and industrial businesses, and will allow us to leverage our global customer relationships and operational excellence."

"Through this transaction, the Tesalca-Texnovo businesses will grow under the ownership of a large, globally recognized premier nonwovens producer," Jose Durany, managing director of Tesalca-Texnovo and member of Grupo Corinpa S.L., said. "This will be a good union between companies with similar goals. We look forward to being long-term partners with PGI."

Jaime Carreras will become the general manager of the new PGI Spain upon closing of the transaction. He has been with Tesalca-Texnovo for over 20 years and has been general manager for Tesalca-Texnovo running daily operations since 2007.

The interests of Grupo Corinpa S.L. were represented by Jose Durany and Juan Pich-Aguilera Roca. Durany was responsible for starting the Tesalca hygiene business in 1999 and has provided senior leadership to the business since then. Durany will become special consultant to PGI to ensure a smooth transition of the acquisition and to provide on-going insight and leadership advice to the PGI board of directors regarding the European market.

The transaction is anticipated to be completed via a two-phase process. In Phase I, PGI will purchase the working capital and operations of the business of Tesalca-Texnovo in exchange for common stock equal to a 5.0 percent ownership stake in PGI. If certain criteria are met, Phase II of the transaction would include the purchase of the remaining assets of Tesalca-Texnovo in exchange for an additional 1.75 percent common stock ownership stake and the assumption or repayment of debt of the business.

Posted in:

Tags: ,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Hot climates worsen chronic kidney disease outcomes